Amicus Therapeutics Presents Data From Clinical Ex Vivo Response Study And Phase 1 Studies Of AT2220

Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced that the Company will present positive results from an ex vivo response study and three Phase 1 studies of AT2

More: continued here

Filed under: Endocrinology on March 14th, 2008